TG Therapeutics, Inc.
$56.87
$0.40 (+0.71%)
$56.18Day Range$57.73
Key Statistics
Market Cap
$8.71B
Shares Outstanding
153.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 14, 1995
Round Lot
100
Locale
US
Trading Data
Day Open
$56.98
Day High
$57.73
Day Low
$56.18
Volume
5.17M
VWAP
$56.92
Prev Close
$56.47
Transactions
--
Acc. Volume
--
About TG Therapeutics, Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
PHARMACEUTICAL PREPARATIONSSIC 2834399 employees2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014(212) 554-4484IPO Dec 14, 1995US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001001316
- Composite FIGI
- BBG000FVZQY1
- Share Class FIGI
- BBG001S8NH06
- Ticker Root
- TGTX
- SIC Code
- 2834
About TG Therapeutics, Inc. (TGTX) Stock
TG Therapeutics, Inc. (TGTX) closed the 2026-09-18 session at $56.87, up 0.71% versus the previous close (+0.40). The stock opened at $56.98 and traded between $56.18 and $57.73 during that session. Session trading volume was 5.2M shares. The volume-weighted average price (VWAP) is $56.92.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
TG Therapeutics, Inc. has a market capitalization of $8.71 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. TGTX is listed on the XNAS exchange. The company employs approximately 399 people. TG Therapeutics, Inc. is headquartered in NEW YORK, NY. The recorded listing date is 1995-12-14.
On this page you can find market TGTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.